📅 PUBMED DAILY TRIAGE — 2026-03-26
Window: 2026-03-25T00:00:00Z → 2026-03-26T09:00:00Z (CRDT, 48h expanded)
Topics scanned: 10 | Articles reviewed: 12
High priority: 1 | Standard: 9 | Low/archive: 2 | Unsolicited finds: 2
Run status: SUCCESS
⚠️ 48h window expansion triggered: zero CRDT results for 2026-03-26 alone (consistent with known indexing lag)
🔴 HIGH PRIORITY
| # | PMID | Title | Score | Why It Matters |
|---|---|---|---|---|
| TR-2026-03-26-001 | 41878633 | Integrative Multi-Omics Analysis Reveals the Characteristic Metabolic Signature of Glioma and Enables Plasma-Based Liquid Biopsy | 8/10 🔴 | Novel 7-metabolite plasma liquid biopsy for glioma achieves AUC=0.964 in adult and 0.925 in pediatric brain tumor validation cohorts (n=430); addresses unmet need for noninvasive glioma diagnostics |
🟢⚪ STANDARD
| # | PMID | Title | Score | Primary Category |
|---|---|---|---|---|
| TR-2026-03-26-002 | 41881502 | Phase II study of olaparib and durvalumab in metastatic castration-resistant prostate cancer | 7/10 🟠 | Treatment Innovation / Genomics — BRCA2-enriched benefit (rPFS 13.2 vs 4.8 mo); IL1R2 as novel response biomarker |
| TR-2026-03-26-003 | 41879223 | ng mt-sDNA vs colonoscopy: 10-year comparative effectiveness modeling | 7/10 🟢 | Early Detection / Public Health — 33% vs 20% CRC mortality reduction; 62% more LYG; real-world adherence driven ⚠️ industry COI |
| TR-2026-03-26-004 | 41881775 | WHO Reporting System for Lymph Node Cytopathology: validation in 2,274 FNABs | 7/10 🟢 | Diagnostics / Hematologic malignancy — 91.8% accuracy; 10mm threshold; site-specific ROM/ROL data |
| TR-2026-03-26-005 | 41881698 | CTI index predicts CV mortality in metabolic syndrome (n=10,421, NHANES) | 6/10 🟢 | Prevention / Cardiometabolic — HR=1.60 highest CTI quartile; novel composite inflammation-IR marker |
| TR-2026-03-26-006 | 41881573 | aGD2-SIRPα fusion antibodies for tumor-selective CD47 blockade in neuroblastoma (preclinical) | 6/10 ⚪ | Treatment Innovation — First proof-of-principal for GD2-targeted CD47 blockade; pediatric neuroblastoma (rare/high unmet need) |
| TR-2026-03-26-007 | 41881346 | Fear of cancer recurrence in HCT survivors: prevalence 34% (n=1,501) | 5/10 🟡 | Public Health / Mental Health — Undertreated survivorship burden in hematologic malignancy patients |
| TR-2026-03-26-008 | 41881813 | Interventions to increase women's cancer screening uptake at first invitation (systematic review) | 5/10 🟢 | Prevention — Self-sampling, SMS, timed appointments increase first-invite attendance; UK data |
| TR-2026-03-26-009 | 41881649 | ★UNSOLICITED★ FATE Registry: T-TEER device failure outcomes (n=2,278, 31 centers) | 6/10 ⬜ | Treatment Innovation — 5.4% device failure rate; reintervention ≈ medical Rx for hard outcomes |
| TR-2026-03-26-010 | 41881745 | Methodological reanalysis: toripalimab histological subgroup in resectable NSCLC | 4/10 ⬜ | Treatment Innovation — Against restricting toripalimab to squamous NSCLC based on underpowered subgroup |
💡 UNSOLICITED FINDS (High-Signal Out-of-Watchlist)
| # | PMID | Title | Score | Signal |
|---|---|---|---|---|
| TR-2026-03-26-009 | 41881649 | Management and Outcome of Failed Transcatheter Tricuspid Edge-to-Edge Repair (FATE Registry) | 6/10 | Large multicenter real-world registry; structural heart disease with high morbidity |
| TR-2026-03-26-011 | 41881641 | TTVI Risk Score Validation: All 3 current scores fail in contemporary cohort (n=457) | 5/10 | Risk model failure identified; calls for new TTVI-specific risk tool development |
🗃️ LOW/ARCHIVE
| # | PMID | Title | Score | Reason |
|---|---|---|---|---|
| TR-2026-03-26-012 | 41879222 | Completion Colonoscopy: Endoscopist selection by screening test type? | 2/10 | No abstract; title-only; scored conservatively |
📊 TODAY'S BREAKDOWN
By research category:
- Early Detection: 3
- Treatment Innovation: 4
- Prevention: 2
- Diagnostics: 2
- Public Health: 2 (overlap with above)
By evidence maturity:
- Exploratory: 2
- Validated: 10
By watchlist topic (articles may match multiple):
- Novel therapeutics / immunotherapy: 3
- Early cancer detection / liquid biopsy: 4
- Hematologic malignancies: 3
- Cardiovascular-metabolic: 1
- Rare diseases: 1
- Sentinel (unsolicited finds): 2
By source type:
- Peer reviewed: 12 | Preprint: 0
Priority distribution:
- HIGH: 1 | STANDARD: 9 | LOW: 2
🔧 RUN NOTES
- Window expansion triggered: 2026-03-26 CRDT returned 0 results across all 4 initial topic queries; expanded to 48h (2026-03-25 to 2026-03-26) per task rules. Consistent with prior run notes (known CRDT indexing lag pattern).
- Deduplication: All 42 fingerprints from state.json checked; zero duplicate PMIDs emitted.
- Truncation: AI/ML topic (134 raw results) and aging/longevity (233 raw results) were truncated; highest-relevance kept per query; logged above.
- COI flag: PMID 41879223 (ng mt-sDNA modeling) — multiple authors affiliated with Exact Sciences Corporation (Cologuard manufacturer). Results should be interpreted cautiously despite validated model.
- Access: All records abstract-only. One record (41878633) has PMC full-text available (PMC13006737) — noted in article JSON.
- No HIGH alerts from prior run fingerprints matched: alert_dedup check passed.
- 1 HIGH priority article identified: TR-2026-03-26-001 (PMID 41878633, glioma liquid biopsy). Telegram alert dispatched per Output C rules.